Aaron Gallego-Crespo

Aaron Gallego-Crespo

Auto-generated profile, based on publicly available information

Aaron Gallego-Crespo

Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2025 in Blood
Verified
Journal Article
Open access
VSViral Shah
Viral Shah
GGGeorge Giotopoulos
George Giotopoulos
HOHikari Osaki
Hikari Osaki
MMMarkus Meyerhöfer
Markus Meyerhöfer
EMEshwar Meduri
Eshwar Meduri
DSDaniel Sasca
Daniel Sasca
Initial clinical trials with drugs targeting epigenetic modulators, such as bromodomain and extraterminal protein (BET) inhibitors, demonstrate modest results in acute myeloid leukemia (AML). A major reason for this involves an increased transcriptional plasticity within AML, which allows the cells to escape therapeutic pressure. In this study, we investigated the immediate epigenetic and transcriptional responses after BET inhibition and demonstrated that BET inhibitor–mediated release of bromodomain-containing protein 4 from chromatin is accompanied by acute compensatory feedback that attenuates downregulation or even increases the expression of specific transcriptional modules. This adaptation is marked at key AML maintenance genes and is mediated by p300, suggesting a rational therapeutic opportunity to improve outcomes by combining BET and p300 inhibition. p300 activity is required during all steps of resistance adaptation; however, the specific transcriptional programs that p300 regulates to induce resistance to BET inhibition differ, in part, between AML subtypes. As a consequence, in some AMLs, the requirement for p300 is highest during the earlier stages of resistance to BET inhibition, when p300 regulates transitional transcriptional patterns that allow leukemia-homeostatic adjustments. In other AMLs, p300 shapes a linear resistance to BET inhibition and remains critical throughout all stages of the evolution of resistance. Altogether, our study elucidates the mechanisms that underlie an “acute” state of resistance to BET inhibition, achieved through p300 activity, and how these mechanisms remodel to mediate “chronic” resistance. Importantly, our data also suggest that sequential treatment with BET and p300 inhibition may prevent resistance development, thereby improving outcomes.

1 July 2025 in Bioinformatics
Verified
Journal Article
Open access
Nelly Selem MojicaNelly Selem Mojica
Nelly Selem Mojica
TLTiago Lubiana
Tiago Lubiana
TPToni Hermoso Pulido
Toni Hermoso Pulido
AGAarón Gallego-Crespo
Aarón Gallego-Crespo
TKTülay Karakulak
Tülay Karakulak
FRFarzana Rahman
Farzana Rahman
Motivation: Wikipedia is a vital open educational resource in computational biology; however, a significant knowledge gap exists between English and non-English Wikipedias. Reducing this knowledge gap via intensive editing events, or “editathons,” would be beneficial in reducing language barriers that disadvantage learners whose native language is not English. Results: We present a framework to guide educators in organizing editathons for learners to improve and create relevant Wikipedia articles. As a case study, we present the results of an editathon held at the 2024 ISCB Latin America conference, in which ten new articles were created for the Spanish-language edition of Wikipedia. We also present a web tool, “compbio-on-wiki,” which identifies relevant English Wikipedia articles missing in other languages. We demonstrate the value of editathons to expand the accessibility and visibility of computational biology content in multiple languages. Availability and implementation: Source code for the compbio-on-wiki Toolforge site is available at: https://github.com/lubianat/compbio-on-wiki

18 March 2026 in Blood
Verified
Journal Article
Closed access
MMMarkus Meyerhöfer
Markus Meyerhöfer
YZYawen Zhou
Yawen Zhou
AGAaron Gallego-Crespo
Aaron Gallego-Crespo
VSViral Shah
Viral Shah
MBMalte Andreas Behrendt
Malte Andreas Behrendt
DSDaniel Sasca
Daniel Sasca
The lysine acetyltransferase (KAT) activity of p300/CREBBP has traditionally been linked to transcriptional activation. This has been attributed largely to acetylation of histone residues such as H3K27ac, a defining hallmark of active regulatory elements. Here we show that, in acute myeloid leukemia (AML), inhibition of p300/CREBBP catalysis can paradoxically increase transcription. We combined time-resolved dynamics of nascent and total transcription with chromatin binding dynamics of p300/CREBBP and their associated TFs/co-regulators (inferred from chromatin pull-down proteomics, acetyl-proteomics and motif enrichment) to uncover mechanisms of transcriptional rewiring after p300/CREBBP catalytic inhibition. In parallel, we dissected the functional contribution of individual p300/CREBBP acetyl-interactome members to KAT inhibition using genome-wide CRISPR-Cas9 dropout and focused Perturb-seq screens. Together, these approaches revealed that KAT inhibition paradoxically retains p300/CREBBP and promotes cooperative TF assembly and increased H3K27 acetylation at a subset of regulatory elements. The effect was most pronounced at IRF motif-enriched loci, including interferon-stimulated genes (ISGs), where KAT inhibition triggered p300/CREBBP accumulation and enhanced combinatorial TF binding, enabling recruitment of the ISG activator STAT1. Consequently, ISG loci were converted into transcriptionally active states that induced cell-cycle arrest, differentiation and apoptosis. Therapeutically, combining KAT inhibition with interferon-alpha augmented ISG expression, synergistically drove AML cell death in vitro and significantly extended survival in both AML xenografts and murine models. These findings refine our understanding of p300/CREBBP KAT activity, demonstrating that cooperative TF assembly can reconfigure p300/CREBBP-containing complexes under catalytic inhibition to induce transcription, with translational implications for reprogramming interferon-driven programs through catalytic inhibition in AML and beyond.